{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:03:09Z","timestamp":1793163789687,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.adro.2025.101937","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:59:55Z","timestamp":1761854395000},"page":"101937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial"],"prefix":"10.1016","volume":"11","author":[{"given":"Enrique","family":"Chajon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Durand-Labrunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Sa","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Le","family":"Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia C.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Dimitriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjin D.","family":"Facer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar I.","family":"Vivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Peiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"de Ba\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101937_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.adro.2025.101937_bib0002","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.adro.2025.101937_bib0003","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101937_bib0004","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.adro.2025.101937_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101760","article-title":"Epidemiology of liver metastases","volume":"67","author":"Horn","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.adro.2025.101937_bib0006","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.23.01781","article-title":"Emerging role of liver transplantation for unresectable colorectal liver metastases","volume":"42","author":"Ch\u00e1vez-Villa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0007","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0008","doi-asserted-by":"crossref","first-page":"183","DOI":"10.14218\/JCTH.2018.00060","article-title":"Role of radiotherapy in the treatment of hepatocellular carcinoma","volume":"7","author":"Chen","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.adro.2025.101937_bib0009","doi-asserted-by":"crossref","first-page":"302","DOI":"10.6004\/jnccn.2019.0019","article-title":"Guidelines insights: Hepatobiliary cancers, version 2.2019","volume":"17","author":"Benson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2025.101937_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis \u2013 clinical outcomes from the international multi-institutional RSSearch\u00ae Patient Registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0011","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.3390\/curroncol30100667","article-title":"Local control following stereotactic body radiation therapy for liver oligometastases: Lessons from a quarter century","volume":"30","author":"Mheid","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0012","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.3390\/cancers14184383","article-title":"The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC)","volume":"14","author":"Kimura","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.adro.2025.101937_bib0013","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2011.07.020","article-title":"Radiotherapy for liver metastases: A review of evidence","volume":"82","author":"H\u00f8yer","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101937_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canrad.2014.05.009","article-title":"Stereotactic body radiation therapy for liver tumours","volume":"18","author":"Maingon","year":"2014","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.adro.2025.101937_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1748-717X-9-150","article-title":"Hafnium oxide nanoparticles: Toward an in vitro predictive biological effect?","volume":"9","author":"Marill","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0016","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.3390\/diagnostics12092156","article-title":"Imaging features of intratumoral injection of NBTXR3 for head and neck squamous cell carcinoma lymph node metastases","volume":"12","author":"Ginat","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.adro.2025.101937_bib0017","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hed.27739","article-title":"International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers","volume":"46","author":"Liem","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.adro.2025.101937_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-023-02938-0","article-title":"Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization","volume":"43","author":"Da Silva","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.adro.2025.101937_bib0019","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/fon.12.96","article-title":"Nanoscale radiotherapy with hafnium oxide nanoparticles","volume":"8","author":"Maggiorella","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2\u20133, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2025.101937_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"4_suppl","key":"10.1016\/j.adro.2025.101937_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.489","article-title":"NRG\/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC)","volume":"41","author":"Dawson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0024","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/j.prro.2019.02.013","article-title":"NRG Oncology\/RTOG 0438: A phase 1 trial of highly conformal radiation therapy for liver metastases","volume":"9","author":"Dawson","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0168-8278(05)80136-9","article-title":"Common bile duct stricture as a late complication of upper abdominal radiotherapy","volume":"20","author":"Cherqui","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.adro.2025.101937_bib0026","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ijrobp.2012.09.012","article-title":"Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system","volume":"85","author":"Eriguchi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101937_bib0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1155\/1992\/52618","article-title":"Radiation stricture of the biliary ducts: An emerging new entity?","volume":"5","author":"Halevy","year":"1992","journal-title":"HPB Surg"},{"key":"10.1016\/j.adro.2025.101937_bib0028","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","article-title":"Protons versus photons for unresectable hepatocellular carcinoma: Liver decompensation and overall survival","volume":"105","author":"Sanford","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101937_bib0029","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.29878","article-title":"Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance","volume":"122","author":"Crane","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101937_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079854","article-title":"Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma","volume":"8","author":"Yoon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.adro.2025.101937_bib0031","article-title":"Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy","volume":"39","author":"Wu","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101937_bib0032","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00066-018-1391-2","article-title":"Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B\u2013C hepatocellular carcinoma","volume":"195","author":"Chiang","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.adro.2025.101937_bib0033","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00066-015-0929-9","article-title":"Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas","volume":"192","author":"Chan","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.adro.2025.101937_bib0034","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/j.ijrobp.2024.07.959","article-title":"Phase IA\/IB study of OAR-based, dose-escalated SBRT with real time adaptive MRI guidance for liver metastases: Preliminary safety and efficacy results","volume":"120","author":"Basree","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425002246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425002246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:36:41Z","timestamp":1776875801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109425002246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452109425002246"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101937","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101937"}}